patients

vVARDIS Drill-Free Solution Curodont Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category

Clinical adoption of Curodont™ is helping to elevate the standard of care in caries management Leading clinical experts herald Curodont™…

2 days ago

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally…

3 days ago

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+

July 22, 2025 02:00 ET  | Source: Scancell Holdings Plc SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent…

3 days ago

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center…

4 days ago

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

July 21, 2025 03:30 ET  | Source: Orion Oyj ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST           Darolutamide…

4 days ago

Manipal Hospital Yeshwanthpur Leads the Charge as Heart Attacks in Young Indians Reach Crisis Levels

BENGALURU, India, July 17, 2025 /PRNewswire/ -- India is witnessing an alarming public health crisis with heart attacks increasingly striking…

1 week ago

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination…

1 week ago

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

1 week ago

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with…

1 week ago

Constant Therapy Announces Collaboration with Burke Rehabilitation to Offer NY’s First AI-Driven Post-Acute Outpatient Speech Therapy

LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Constant Therapy today announced a first-in-state collaboration with New York-based Burke Rehabilitation…

1 week ago